CorMedix (CRMD) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CRMD Stock Forecast

CorMedix stock forecast is as follows: an average price target of $9.00 (represents a 5.02% upside from CRMD’s last price of $8.57) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

CRMD Price Target

The average price target for CorMedix (CRMD) is $9.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential 5.02% upside from CRMD's last price of $8.57.

CRMD Analyst Ratings

Buy

According to 3 Wall Street analysts, CorMedix's rating consensus is 'Buy'. The analyst rating breakdown for CRMD stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).

CorMedix Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Mar 13, 2024	Gregory Renza	RBC Capital	$9.00	$3.90	130.77%	5.02%

The latest CorMedix stock forecast, released on Mar 13, 2024 by Gregory Renza from RBC Capital, set a price target of $9.00, which represents a 130.77% increase from the stock price at the time of the forecast ($3.90), and a 5.02% increase from CRMD last price ($8.57).

CorMedix Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$9.00
Last Closing Price	$8.57	$8.57	$8.57
Upside/Downside	-100.00%	-100.00%	5.02%

In the current month, the average price target of CorMedix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CorMedix's last price of $8.57. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	New Rating	Rating Change
Aug 26, 2024	Rodman & Renshaw	Buy	Initialise
Aug 10, 2023	RBC Capital	Outperform	Initialise
Apr 25, 2022	Zacks Investment Research	Sell	Downgrade

CorMedix's last stock rating was published by Rodman & Renshaw on Aug 26, 2024. The company Initialise its CRMD rating from "null" to "Buy".

CorMedix Financial Forecast

CorMedix Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Jun 14
Revenue	-	-	-	-	-	-	-	-	-	$29.70K	$7.64K	$56.40K	$38.09K	$8.19K	$88.26K	$55.71K	$93.02K	$16.44K	$74.05K	$24.78K	$59.53K	$35.27K	$163.69K	$23.21K	$39.56K	$41.43K	$31.26K	$39.73K
Avg Forecast	$57.49M	$47.31M	$38.31M	$31.02M	$19.59M	$10.35M	$1.67M	$3.00M	$-333.33K	$2.33K	$25.00K	$19.00K	$20.00K	$43.25K	$39.60K	$46.25K	$28.75K	$117.50K	$250.00K	$92.50K	$80.00K	$128.00K	$59.50K	$14.29K	$32.42K	$30.00K	$11.74K	$99.20K
High Forecast	$58.69M	$48.30M	$39.11M	$31.67M	$20.00M	$10.56M	$1.67M	$3.06M	$-328.32K	$2.38K	$25.00K	$19.00K	$20.00K	$43.25K	$39.60K	$46.25K	$28.75K	$117.50K	$250.00K	$92.50K	$80.00K	$128.00K	$59.50K	$17.14K	$38.90K	$36.00K	$14.09K	$119.04K
Low Forecast	$56.62M	$46.60M	$37.73M	$30.55M	$19.30M	$10.19M	$1.67M	$2.95M	$-340.30K	$2.30K	$25.00K	$19.00K	$20.00K	$43.25K	$39.60K	$46.25K	$28.75K	$117.50K	$250.00K	$92.50K	$80.00K	$128.00K	$59.50K	$11.43K	$25.93K	$24.00K	$9.39K	$79.36K
# Analysts	1	1	1	1	2	1	2	2	4	1	1	2	2	2	2	9	9	9	9	5	5	5	5	12	14	20	9	8
Surprise %	-	-	-	-	-	-	-	-	-	12.73%	0.31%	2.97%	1.90%	0.19%	2.23%	1.20%	3.24%	0.14%	0.30%	0.27%	0.74%	0.28%	2.75%	1.62%	1.22%	1.38%	2.66%	0.40%

CorMedix's average Quarter revenue forecast for Dec 23 based on 4 analysts is $-333.33K, with a low forecast of $-340.30K, and a high forecast of $-328.32K. CRMD's average Quarter revenue forecast represents a -1222.26% decrease compared to the company's last Quarter revenue of $29.70K (Dec 22).

CorMedix EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Jun 14
# Analysts	1	1	1	1	2	1	2	2	4	1	1	2	2	2	2	9	9	9	9	5	5	5	5	12	14	20	9	8
EBITDA	-	-	-	-	-	-	-	-	-	$-8.21M	$-7.00M	$-7.77M	$-8.55M	$-5.87M	$-7.20M	$-6.00M	$-6.58M	$-8.92M	$-5.53M	$-5.28M	$-5.08M	$-5.43M	$-4.85M	$-10.16M	$-7.56M	$-4.23M	$-5.49M	$3.51M
Avg Forecast	$-34.49M	$-28.39M	$-22.98M	$-18.61M	$-11.76M	$-6.21M	$-1.00M	$-1.80M	$200.00K	$-1.40K	$-8.28M	$-11.40K	$-12.00K	$-25.95K	$-6.40M	$-27.75K	$-17.25K	$-70.50K	$-6.01M	$-55.50K	$-48.00K	$-76.80K	$-5.88M	$-6.10M	$-5.81M	$-2.82M	$-3.36M	$-59.52K
High Forecast	$-33.97M	$-27.96M	$-22.64M	$-18.33M	$-11.58M	$-6.11M	$-1.00M	$-1.77M	$204.18K	$-1.38K	$-6.63M	$-11.40K	$-12.00K	$-25.95K	$-5.12M	$-27.75K	$-17.25K	$-70.50K	$-4.81M	$-55.50K	$-48.00K	$-76.80K	$-4.71M	$-4.88M	$-4.65M	$-2.25M	$-2.69M	$-47.62K
Low Forecast	$-35.21M	$-28.98M	$-23.46M	$-19.00M	$-12.00M	$-6.34M	$-1.00M	$-1.84M	$196.99K	$-1.43K	$-9.94M	$-11.40K	$-12.00K	$-25.95K	$-7.68M	$-27.75K	$-17.25K	$-70.50K	$-7.22M	$-55.50K	$-48.00K	$-76.80K	$-7.06M	$-7.32M	$-6.98M	$-3.38M	$-4.03M	$-71.42K
Surprise %	-	-	-	-	-	-	-	-	-	5865.42%	0.84%	681.19%	712.20%	226.11%	1.13%	216.25%	381.61%	126.50%	0.92%	95.16%	105.76%	70.70%	0.82%	1.67%	1.30%	1.50%	1.64%	-58.95%

9 analysts predict CRMD's average Quarter EBITDA for Mar 15 to be $-3.36M, with a high of $-2.69M and a low of $-4.03M. This is -195.69% lower than CorMedix's previous annual EBITDA (Jun 14) of $3.51M.

CorMedix Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Jun 14
# Analysts	1	1	1	1	2	1	2	2	4	1	1	2	2	2	2	9	9	9	9	5	5	5	5	12	14	20	9	8
Net Income	-	-	-	-	-	-	-	-	-	$-8.03M	$-7.04M	$-7.80M	$-8.57M	$-4.63M	$-7.22M	$-6.09M	$-6.60M	$-3.78M	$-5.56M	$-5.30M	$-5.26M	$-696.16K	$-5.17M	$-10.19M	$-7.60M	$-4.23M	$-5.50M	$3.51M
Avg Forecast	$19.41M	$15.29M	$11.77M	$8.82M	$1.76M	$-7.18M	$-14.76M	$-16.29M	$-11.83M	$-10.99M	$-8.31M	$-13.44M	$-10.18M	$-10.37M	$-6.42M	$-12.68M	$-14.69M	$-13.83M	$-6.04M	$-13.83M	$-14.41M	$-12.39M	$-6.28M	$-6.11M	$-5.82M	$-2.82M	$-3.36M	$5.04M
High Forecast	$19.94M	$15.71M	$12.09M	$9.06M	$1.81M	$-7.04M	$-14.47M	$-15.97M	$-11.60M	$-10.78M	$-6.65M	$-13.44M	$-10.18M	$-10.37M	$-5.13M	$-12.68M	$-14.69M	$-13.83M	$-4.83M	$-13.83M	$-14.41M	$-12.39M	$-5.02M	$-4.89M	$-4.66M	$-2.26M	$-2.69M	$6.05M
Low Forecast	$19.03M	$15.00M	$11.54M	$8.65M	$1.73M	$-7.37M	$-15.16M	$-16.73M	$-12.15M	$-11.29M	$-9.98M	$-13.44M	$-10.18M	$-10.37M	$-7.70M	$-12.68M	$-14.69M	$-13.83M	$-7.25M	$-13.83M	$-14.41M	$-12.39M	$-7.53M	$-7.33M	$-6.99M	$-3.38M	$-4.03M	$4.03M
Surprise %	-	-	-	-	-	-	-	-	-	0.73%	0.85%	0.58%	0.84%	0.45%	1.13%	0.48%	0.45%	0.27%	0.92%	0.38%	0.37%	0.06%	0.82%	1.67%	1.31%	1.50%	1.64%	0.70%

CorMedix's average Quarter net income forecast for Mar 15 is $-3.36M, with a range of $-4.03M to $-2.69M. CRMD's average Quarter net income forecast represents a -195.74% decrease compared to the company's last Quarter net income of $3.51M (Jun 14).

CorMedix SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Jun 14
# Analysts	1	1	1	1	2	1	2	2	4	1	1	2	2	2	2	9	9	9	9	5	5	5	5	12	14	20	9	8
SG&A	-	-	-	-	-	-	-	-	-	$5.58M	$4.75M	$4.55M	$3.84M	$3.36M	$4.60M	$3.79M	$3.69M	$3.23M	$3.17M	$2.68M	$2.63M	$2.57M	$1.98M	$1.90M	$2.64M	$2.16M	$4.28M	$1.70M
Avg Forecast	$5.58B	$4.59B	$3.72B	$3.01B	$1.90B	$1.00B	$161.82M	$291.19M	$-32.35M	$226.45K	$2.43M	$1.84M	$1.94M	$4.20M	$3.84M	$4.49M	$2.79M	$11.40M	$24.27M	$8.98M	$7.77M	$12.42M	$5.78M	$1.39M	$3.15M	$2.91M	$1.14M	$9.63M
High Forecast	$5.70B	$4.69B	$3.80B	$3.07B	$1.94B	$1.03B	$161.83M	$297.28M	$-31.87M	$231.11K	$2.43M	$1.84M	$1.94M	$4.20M	$3.84M	$4.49M	$2.79M	$11.40M	$24.27M	$8.98M	$7.77M	$12.42M	$5.78M	$1.66M	$3.78M	$3.49M	$1.37M	$11.55M
Low Forecast	$5.50B	$4.52B	$3.66B	$2.97B	$1.87B	$989.10M	$161.81M	$286.81M	$-33.03M	$222.95K	$2.43M	$1.84M	$1.94M	$4.20M	$3.84M	$4.49M	$2.79M	$11.40M	$24.27M	$8.98M	$7.77M	$12.42M	$5.78M	$1.11M	$2.52M	$2.33M	$911.42K	$7.70M
Surprise %	-	-	-	-	-	-	-	-	-	24.62%	1.96%	2.47%	1.98%	0.80%	1.20%	0.84%	1.32%	0.28%	0.13%	0.30%	0.34%	0.21%	0.34%	1.37%	0.84%	0.74%	3.75%	0.18%

CorMedix's average Quarter SG&A projection for Dec 23 is $-32.35M, based on 4 Wall Street analysts, with a range of $-33.03M to $-31.87M. The forecast indicates a -680.32% fall compared to CRMD last annual SG&A of $5.58M (Dec 22).

CorMedix EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Jun 14
# Analysts	1	1	1	1	2	1	2	2	4	1	1	2	2	2	2	9	9	9	9	5	5	5	5	12	14	20	9	8
EPS	-	-	-	-	-	-	-	-	-	$-0.19	$-0.18	$-0.20	$-0.22	$-0.12	$-0.20	$-0.19	$-0.22	$-0.14	$-0.21	$-0.21	$-1.35	$-0.03	$-0.22	$-0.70	$-0.95	$-0.60	$-1.15	$0.60
Avg Forecast	$0.33	$0.26	$0.20	$0.15	$0.03	$-0.12	$-0.25	$-0.28	$-0.20	$-0.19	$-0.22	$-0.23	$-0.18	$-0.18	$-0.18	$-0.22	$-0.26	$-0.24	$-0.23	$-0.24	$-0.25	$-0.21	$-0.28	$-0.30	$-0.59	$-0.06	$-0.06	$-0.89
High Forecast	$0.34	$0.27	$0.21	$0.15	$0.03	$-0.12	$-0.25	$-0.27	$-0.20	$-0.18	$-0.22	$-0.23	$-0.18	$-0.18	$-0.18	$-0.22	$-0.26	$-0.24	$-0.23	$-0.24	$-0.25	$-0.21	$-0.28	$-0.24	$-0.47	$-0.05	$-0.04	$-0.71
Low Forecast	$0.32	$0.25	$0.20	$0.15	$0.03	$-0.13	$-0.26	$-0.28	$-0.21	$-0.19	$-0.22	$-0.23	$-0.18	$-0.18	$-0.18	$-0.22	$-0.26	$-0.24	$-0.23	$-0.24	$-0.25	$-0.21	$-0.28	$-0.36	$-0.71	$-0.07	$-0.07	$-1.07
Surprise %	-	-	-	-	-	-	-	-	-	1.02%	0.82%	0.86%	1.25%	0.67%	1.09%	0.86%	0.86%	0.58%	0.91%	0.88%	5.40%	0.14%	0.77%	2.33%	1.61%	10.00%	19.17%	-0.67%

According to 9 Wall Street analysts, CorMedix's projected average Quarter EPS for Mar 15 is $-0.06, with a low estimate of $-0.07 and a high estimate of $-0.04. This represents a -110.00% decrease compared to CRMD previous annual EPS of $0.60 (Jun 14).

CorMedix Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PGEN	Precigen	$0.69	$6.00	769.57%	Buy
GOSS	Gossamer Bio	$0.87	$3.75	331.03%	Buy
SGMO	Sangamo Therapeutics	$2.82	$12.00	325.53%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
CELC	Celcuity	$12.55	$39.00	210.76%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
NUVB	Nuvation Bio	$2.81	$7.00	149.11%	Buy
ALDX	Aldeyra Therapeutics	$5.33	$12.00	125.14%	Buy
REPL	Replimune Group	$11.72	$19.00	62.12%	Buy
ELVN	Enliven Therapeutics	$24.39	$39.50	61.95%	Buy
CNTB	Connect Biopharma	$1.06	$1.50	41.51%	Buy
TVTX	Travere Therapeutics	$17.14	$21.75	26.90%	Buy
TARS	Tarsus Pharmaceuticals	$53.26	$63.00	18.29%	Buy
CRMD	CorMedix	$8.54	$9.00	5.39%	Buy
KRON	Kronos Bio	$0.96	$1.00	4.17%	Buy
ETON	Eton Pharmaceuticals	$12.64	$13.00	2.85%	Buy

CRMD Forecast FAQ

Is CorMedix a good buy?

Yes, according to 3 Wall Street analysts, CorMedix (CRMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of CRMD's total ratings.

What is CRMD's price target?

CorMedix (CRMD) average price target is $9 with a range of $9 to $9, implying a 5.02% from its last price of $8.57. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CorMedix stock go up soon?

According to Wall Street analysts' prediction for CRMD stock, the company can go up by 5.02% (from the last price of $8.57 to the average price target of $9), up by 5.02% based on the highest stock price target, and up by 5.02% based on the lowest stock price target.

Can CorMedix stock reach $13?

CRMD's average twelve months analyst stock price target of $9 does not support the claim that CorMedix can reach $13 in the near future.

What are CorMedix's analysts' financial forecasts?

CorMedix's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $34.61M (high $35.29M, low $34.11M), average EBITDA is $-20.763M (high $-20.466M, low $-21.176M), average net income is $-36.464M (high $-35.668M, low $-37.538M), average SG&A $3.36B (high $3.43B, low $3.31B), and average EPS is $-0.62 (high $-0.606, low $-0.638). CRMD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $174.12M (high $177.76M, low $171.5M), average EBITDA is $-104M (high $-103M, low $-107M), average net income is $55.3M (high $56.8M, low $54.22M), average SG&A $16.9B (high $17.25B, low $16.65B), and average EPS is $0.94 (high $0.966, low $0.922).

Did the CRMD's actual financial results beat the analysts' financial forecasts?

Based on CorMedix's last annual report (Dec 2022), the company's revenue was $65.41K, beating the average analysts forecast of $27.33K by 139.30%. Apple's EBITDA was $-30.298M, beating the average prediction of $-8.284M by 265.73%. The company's net income was $-29.702M, beating the average estimation of $-19.306M by 53.85%. Apple's SG&A was $20.01M, beating the average forecast of $2.65M by 654.09%. Lastly, the company's EPS was $-0.74, beating the average prediction of $-0.407 by 81.88%. In terms of the last quarterly report (Dec 2022), CorMedix's revenue was $29.7K, beating the average analysts' forecast of $2.33K by 1173.12%. The company's EBITDA was $-8.206M, beating the average prediction of $-1.399K by 586441.96%. CorMedix's net income was $-8.029M, missing the average estimation of $-10.993M by -26.96%. The company's SG&A was $5.58M, beating the average forecast of $226.45K by 2362.07%. Lastly, the company's EPS was $-0.19, beating the average prediction of $-0.187 by 1.67%